series-c-plus
Stage
2
Investors
About
Synthekine designs and develops engineered cytokine therapeutics, including cytokine partial agonists and surrogate cytokine agonists, to treat cancers and autoimmune, inflammatory, and metabolic diseases. Their pipeline includes programs such as STK-012 and the SYNERGY-101 Phase 2 study in non-small cell lung cancer.
Explore Synthekine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.